Background
==========

Recent data suggest that the Arg72Pro polymorphism of the *TP53*gene is correlated to *TP53*mutations and prognosis in breast cancer \[[@B1],[@B2]\]. In addition, LOH with retention of the Arg allele has been associated with reduced disease-free survival and overall survival \[[@B3]\].

Patients and methods
====================

In the period January 1990--1994 a consecutive cohort of 204 Danish women were diagnosed with primary breast cancer. *TP53*mutations were assessed by denaturing gradient gel electrophoresis analysis and DNA sequencing. The Arg72Pro polymorphism was measured in DNA extracted from blood lymphocytes and LOH was measured in DNA extracted from invasive breast carcinomas by a method including PCR, primer extension reactions and denaturing high-performance liquid chromatography analyses \[[@B4]\].

Results
=======

Mutations in the *TP53*gene in tumour DNA were associated with a significantly higher probability of distant metastases (*P*\< 0.0001). The Arg72Pro polymorphism was neither significantly associated with *TP53*mutations (*P*\> 0.2) nor with probability of distant metastases (*P*\> 0.2). Among patients heterozygous at *TP53*codon 72, LOH in tumour tissue was significantly associated with *TP53*mutations -- with 10 out of 40 patients with LOH carrying a *TP53*mutation but only one out of 28 patients with no LOH (*P*= 0.04). However, patients with LOH at *TP53*codon 72 did not have a significantly higher probability of distant metastases as compared with patients with no LOH (*P*\> 0.2). But within the group of patients with LOH, a significantly higher probability of distant metastases was found for patients with retention of the Pro allele (11/24) as compared with patients with retention of the Arg allele (2/16) (*P*= 0.04). Among patients with retention of Pro, five patients out of 24 patients (21%) had *TP53*mutations as compared with five patients out of 16 patients (31%) with retention of Arg.

Conclusion
==========

Our findings suggest that the Arg72Pro polymorphism is neither associated with *TP53*mutations nor with breast cancer prognosis. However, LOH at codon 72 among heterozygous patients might be associated with *TP53*mutations, and patients with retention of the Pro allele might experience a poorer prognosis as compared with patients with retention of the Arg allele.
